[Granulomatous vasculitides and vasculitides with extravascular granulomatosis]

[Granulomatosis with polyangiitis and microscopic polyangiitis]

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are two entities of ANCA-associated vasculitis (AAV). Both diseases are characterised by systemic necrotising small-vessel vasculitis, which can affect any organ. In GPA, extravascular necrotising granulomatous inflammation, usually affecting the respiratory tract, is found in addition. In the majority of cases, the clinical presentation is dominated by a pulmonary-renal syndrome with alveolar haemorrhage and rapidly progressive glomerulonephritis. Other organ involvement is found as well. In GPA, the upper respiratory tract is commonly affected. GPA is associated with anti-neutrophil cytoplasmic autoantibodies (ANCA) with specificity for proteinase 3 (PR3-ANCA) and MPA with specificity for myeloperoxidase (MPO-ANCA). Immunosuppressive therapy depends on disease activity and the severity of organ involvement.

The role of anti-eosinophilic therapies in eosinophilic granulomatosis with polyangiitis: a systematic review

Eosinophilic granulomatosis with polyangiitis (EGPA) is an antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, mostly affecting small-sized arteries and usually occurring in patients with an allergic background. Eosinophils seem to play a significant role in the pathogenesis of the disease and, therefore, biologics targeting interleukin 5 (IL5), a cytokine tightly linked to eosinophils, have emerged as a promising therapeutic tool. A systematic review of Medline was conducted from 2007 to 2022 to search for data regarding the use of anti-IL5 therapies in patients with EGPA. Ongoing or unpublished trials were also searched in ClinicalTrials.gov and the World Health Organization trials portal. The efficacy and safety of mepolizumab, an anti-IL5 monoclonal antibody (mAb), was confirmed by a randomized controlled trial (RCT), although a significant proportion of patients did not respond to this treatment. Other studies showed that both doses of 100 mg and 300 mg of mepolizumab are almost equally effective in EGPA. Benralizumab, an anti-IL5 receptor mAb has preliminary promising results and an RCT is planned to be conducted. Apart from their clinical efficacy in EGPA, anti-IL5 therapies may have steroid-sparing properties. Anti-IL5 therapies seem to be effective and safe in patients with refractory/relapsing EGPA and can be used as a steroid-sparing treatment. Nevertheless, more research is needed to clarify the pathophysiology of the disease; this may potentially lead to the identification of biomarkers to pinpoint patients most likely to respond to anti-IL5-blockade.

Clinical and vascular lesion characteristics of the patients with takayasu arteritis manifested firstly as acute myocardial infarction at onset

Objective

To explore clinical and vascular lesion characteristics of the patients with Takayasu arteritis (TA) manifested firstly as acute myocardial infarction (AMI) at onset and to improve the diagnostic rate of TA.

Methods

The clinical and angiographic data of six patients with TA manifested firstly as AMI at onset were retrospectively analyzed.

Results

Of six patients (16-25 years old), 83.33% (five cases) was female, three patients had a history of hypertension and three patients did not have any medical history. One patient had intermittent effort chest tightness. On admission patients all presented with chest pain, dyspnea, hypotension, cardiogenic shock, abnormal electrocardiogram, and elevated cardiac troponin I. The vessel involvement was left coronary main trunk 83.33%, left anterior descending artery 33.33% and left circumflex branch 16.67%, right coronary artery 66.67%, subclavian artery 83.33%, and renal artery 50%. Five patients received the emergency PCI. One patient died of heart failure. During follow-up 3 patients received again PCI treatment.

Conclusion

Clinical and vascular lesion characteristics of those patients were no discomfort before admission, and the suddenly typical manifestation of AMI. Severe stenosis or occlusion occurred in main coronary artery ostia and peripheral large artery. For the TA patients with hemodynamic instability the effectiveness of emergency PCI is positive.

Granulomatose mit Polyangiitis und mikroskopische Polyangiitis

Die Granulomatose mit Polyangiitis (GPA) und mikroskopische Polyangiitis (MPA) sind zwei zur ANCA-assoziierten Vaskulitis (AAV) zählende Entitäten. Beiden Erkrankungen liegt eine systemische nekrotisierende Kleingefäßvaskulitis zugrunde, die jedes Organ betreffen kann. Bei der GPA ist zusätzlich eine in der Regel den Respirationstrakt betreffende extravaskuläre nekrotisierende granulomatöse Entzündung vorzufinden. Das klinische Bild wird in der Mehrzahl der Fälle durch ein pulmo-renales Syndrom mit alveolärer Hämorrhagie und rapid-progressiver Glomerulonephritis sowie weitere Organmanifestationen bestimmt. Bei der GPA imponiert zudem die fast regelhafte Mitbeteiligung des oberen Respirationstrakts. Die GPA ist mit Anti-Neutrophilen zytoplasmatischen Autoantikörpern (ANCA) mit einer Spezifität für die Proteinase 3 (PR3-ANCA) und die MPA für Myeloperoxidase (MPO-ANCA) assoziiert. Die immunsuppressive Therapie richtet sich nach der Krankheitsaktivität und Schwere der Organbeteiligung.